About Quotient Diagnostics
Quotient Diagnostics is a Healthcare company based in Walton-on-thames (United Kingdom) founded in 2003 by Phillip Vessey, and was acquired by EKF in September 2010. It operates as a glycated haemoglobin analysers are developed to monitor diabetes treatment. Quotient Diagnostics has raised $1.41 million across 1 funding round from investors including EKF, Succes Europe and Italian Angels for Growth. The company has 1 employees. Its focus areas include Life Sciences, Diabetes and In-Vitro Diagnostics. Its legal entity is QUOTIENT DIAGNOSTICS LIMITED. Its competitors include Viome Life Sciences, Proteomics International, Tethys BioScience, Mellitus and SmartZyme and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
Quotient Diagnostics was founded in 2003 as a spin-out from Chelsea Technologies Group in the healthcare diagnostics sector. HbA1c analysers are developed by the company using a patented fluorescent quenching technique for diabetes monitoring. The firm was acquired by EKF Diagnostics, a publicly listed healthcare company, in 2010 for approximately 5.35 million. Operations are now focused on RD and manufacturing for EKFs HbA1c analysers, with a base in the UK.
- Headquarters Walton-on-thames, United Kingdom
- Employees 1
- Founders Phillip Vessey
- Stage Acquired
- SectorsHealthcare
- Website quotientdiagnostics.co.uk
- Acquired by EKF (Sep 2010)
- Legal Name Quotient Diagnostics Limited
Funding Insights of Quotient Diagnostics
Quotient Diagnostics has successfully raised a total of $1.41M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.41 million completed in July 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.41M
- Total Rounds 1
- Last Round Series A — $1.41M
- First Round $1.41M
(Jul 2009)
- Investors Count 2
All 1 funding rounds of Quotient Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2009 | $1.41M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Quotient Diagnostics
Quotient Diagnostics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include EKF, Succes Europe and Italian Angels for Growth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | succes-europe.com | - | |
A network of business angels is formed to support innovative startups. | – | italianangels.net | Milan, Italy | |
Point-of-care and laboratory blood analyzers are developed by EKF. | 1990 | ekfdiagnostics.com | Penarth, United Kingdom |
Investor details for Quotient Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Quotient Diagnostics
1 people are tracked at Quotient Diagnostics (1 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Phillip Vessey | Founder | Leadership |
Complete people profiles for Quotient Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Quotient Diagnostics
3 dated milestones of Quotient Diagnostics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Quotient Diagnostics is founded.
- Funding First funding round of $1.4M.
- Exit Acquired by EKF.
Competitors of Quotient Diagnostics
Quotient Diagnostics has 9 listed competitors in our database, 6 of them funded. They include Viome Life Sciences, Proteomics International, Tethys BioScience, Mellitus and SmartZyme, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viomelifesciences.com | 2016 | Bothell, United States | $92.44M | 136 | Provider of tests to prevent, treat, and cure chronic diseases, and cancer | |
| proteomics.com.au | 2001 | Perth, Australia | – | – | Medical technology company at the forefront of predictive diagnostics and bio-analytical services | |
| tethysbio.com | 2002 | Emeryville, United States | $53.3M | 81 | Develops biological markers for medical diagnostic applications. | |
| mellitusllc.com | 2011 | Boston, United States | $16.1M | – | In vitro diagnostic test for Gestational Diabetes Mellitus (GDM) | |
| smzyme.com | 2013 | Herzliya Pituach, Israel | $4M | – | Proprietary protein engineering technology is developed for diabetes products. | |
| thescoutds.com | 2004 | Albuquerque, United States | $25.23M | – | Offers biomarker screening solutions for early diabetes detection. | |
| sensotrend.com | 2013 | Tampere, Finland | – | – | Automated diabetes diary is offered for blood sugar monitoring. | |
| accessiblediagnostics.com | 2014 | Greenville, United States | $548,500 | – | Delivers comprehensive glucose monitoring device solutions. | |
| patiadiabetes.com | 2013 | Mexico | – | – | Genetic tests for type 2 diabetes risk assessment are developed. |
Detailed competitors of Quotient Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Quotient Diagnostics
Websites that share an audience with Quotient Diagnostics (quotientdiagnostics.co.uk).
Websites whose visitors overlap most with Quotient Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Diabetes
10 companies that operate in the same segment as Quotient Diagnostics (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 237 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Quotient Diagnostics
Quotient Diagnostics was founded in 2003 and raised its 1st funding round 6 years after it was founded.
Quotient Diagnostics is headquartered in Walton-on-thames, United Kingdom. It is registered at Walton-on-thames, Surrey, United Kingdom.
Quotient Diagnostics is a funded company, having raised a total of $1.41M across 1 funding round to date. The company's 1st funding round was a Series A of $1.41M, raised on Jul 2009.
Quotient Diagnostics has 1 employees.
Quotient Diagnostics was founded in 2003 as a spin-out from Chelsea Technologies Group in the healthcare diagnostics sector. HbA1c analysers are developed by the company using a patented fluorescent quenching technique for diabetes monitoring. The firm was acquired by EKF Diagnostics, a publicly listed healthcare company, in 2010 for approximately 5.35 million. Operations are now focused on RD and manufacturing for EKFs HbA1c analysers, with a base in the UK.
Quotient Diagnostics's top competitors include Viome Life Sciences, Proteomics International and Mellitus.
Quotient Diagnostics has 3 investors. Key investors include EKF, Succes Europe, and Italian Angels for Growth.
Quotient Diagnostics operates through Quotient Diagnostics Limited.
Yes. Quotient Diagnostics was acquired by EKF in September 2010.